---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005517"
form_type: "8-K"
ticker: null
cik: "0001610618"
company_name: "Cidara Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:22:00.885602+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Merck completes acquisition of Cidara Therapeutics for $221.50 per share

## Summary
- Tender offer expired Jan 6 with 27,149,333 common shares and 89,956 Series A shares validly tendered, representing ~88.3% of total voting shares.
- Each common share converted to $221.50 cash; each Series A share converted to $15,505.00 cash, without interest.
- Common shares delisted from Nasdaq effective Jan 7; company will file Form 15 to terminate SEC registration and reporting obligations.
- Board replaced by Merck designees Jon Filderman, Melissa Leonard, Dalton Smart; prior directors resigned.
- Company's equity incentive plans and stock purchase plan terminated at the Effective Time.

## SEC filing metadata
- accession: 0001193125-26-005517
- form_type: 8-K
- cik: 0001610618
- company_name: Cidara Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/0001193125-26-005517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/d57313d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005517
- JSON: https://secwatch.observer/filing/0001193125-26-005517.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005517.txt

## Source-grounded claims
- claim_id: 8ce4aa91574bf9922b7cf864c87570aa8dff701f
  claim: Cidara Therapeutics, Inc.: Amended and restated certificate of incorporation and bylaws in connection with merger.
  evidence_excerpt: Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s amended and restated certificate of incorporation, as amended, and amended and restated bylaws were amended and restated in their entirety in the forms filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/0001193125-26-005517-index.htm
- claim_id: 068866b627a463c941fbf89ea15586c99872bea4
  claim: Cidara Therapeutics, Inc. underwent a change of control involving Merck Sharp & Dohme LLC for $221.50 per Common Share in cash and $15,505.00 per Series A Convertible Voting Preferred Share in cash (closed 2026-01-07).
  evidence_excerpt: 5, 2025, Purchaser commenced a tender offer to acquire (i) all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Common Shares ”), for $221.50 per Common Share (the “ Common Share Offer Price ”) and (ii) all of the outstanding shares of Series A Convertible Voting Preferred Stock of the Company, par value $0.0001 per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/0001193125-26-005517-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.